Anticoagulation Appears Safe for Patients With Brain Mets

This article originally appeared here.
Share this content:
Anticoagulation Appears Safe for Patients With Brain Mets
Anticoagulation Appears Safe for Patients With Brain Mets

WEDNESDAY, June 3, 2015 (HealthDay News) -- Therapeutic anticoagulation is safe for treating venous thromboembolism in patients with cancer that has metastasized to the brain, according to new research. The study was published online May 18 in Blood.

The study included 293 patients with brain metastases and venous thromboembolism. The patients were randomly selected to receive enoxaparin (Lovenox) or no anticoagulation medication.

After 12 months, the incidence of intracranial hemorrhage was 44 percent for people taking enoxaparin. In those who didn't take the medication, 37 percent experienced intracranial hemorrhage; however, this was not a statistically significant difference (P = 0.13). Overall survival was similar for both groups.

"While it is a very common clinical scenario to treat a patient with a metastatic brain tumor who also develops a blood clot, before this study there was very little data to inform the difficult decision of whether or not to anticoagulate these patients," senior author Jeffrey Zwicker, M.D., of Beth Israel Deaconess Medical Center and Harvard Medical School in Boston, said in a news release from the American Society of Hematology. "Our findings, which demonstrate that current practice is safe, should reassure physicians that anticoagulants can be safely administered to patients with brain metastases and a history of blood clots."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA OKs Doptelet for Liver Dz Patients Undergoing Procedures

FDA OKs Doptelet for Liver Dz Patients Undergoing ...

Doptelet reduces the need for platelet transfusion or any rescue therapy on day of procedure

Slower Decline in Lung Function With Anthocyanin Intake

Slower Decline in Lung Function With Anthocyanin Intake

Slower annual rates of decline in FEV1 and FVC for those in highest quartile of anthocyanin intake

Bioengineering Feasible for Airway Reconstruction

Bioengineering Feasible for Airway Reconstruction

Bioengineered tracheal and bronchial reconstruction reported using stented aortic matrices

is free, fast, and customized just for you!

Already a member?

Sign In Now »